The clinical outcomes and prognostic factors of dedifferentiated central chondrosarcoma in extremities.
Clinical outcomes
Dedifferentiated Central Chondrosarcoma
Overall survival
Prognostic factor
Surgical Margin
Journal
Journal of orthopaedic surgery and research
ISSN: 1749-799X
Titre abrégé: J Orthop Surg Res
Pays: England
ID NLM: 101265112
Informations de publication
Date de publication:
03 Oct 2024
03 Oct 2024
Historique:
received:
24
03
2024
accepted:
19
09
2024
medline:
4
10
2024
pubmed:
4
10
2024
entrez:
4
10
2024
Statut:
epublish
Résumé
This study was to analyze the clinical outcomes and prognostic factors of dedifferentiated central chondrosarcomas (DCCS) in extremities. A retrospective study was conducted on 49 patients (27 males, 22 females) who underwent surgical treatment between January 2001 and March 2023 in our institution. All patients were diagnosed with dedifferentiated central chondrosarcomas by needle biopsy or postoperative histopathological examination. The general characters, treatment and clinical outcomes were recorded in the follow-up and all surgical-related complications that occurred were recorded in this study. Overall, these data were used to analyse the prognostic factors of DCCS. 49 patients were included in this retrospective study and there were no patients lost in the follow-up period. The median diagnosis age of all patients was 57 years old (ranging from 17 to 87) and the median follow-up time was 34 months (range, 1-289). The average tumor size was 9.6 ± 2.4 cm (3.0-15.5). Median overall survival (OS) and progression-free survival (PFS) were 34 and 23 months, respectively. The 1-year, 2-year, 5-year, and 10-year OS were 87.8% (95% CI 77.6%-98.0%), 71.4% (35/49), 28.6% (14/49) and 18.4% (9/49). And the 1-year, 2-year, 5-year, and 10-year PFS were 75.5% (95% CI 63.6%-87.4%), 49.0% (35/49), 26.5% (14/49) and 16.3% (9/49). Multiple variate analyses indicated metastasis, pathological fracture, Enneking staging and surgical margin were independent prognostic factors in extremity dedifferentiated central chondrosarcomas. Dedifferentiated central chondrosarcomas in extremities still had a grave prognosis. Metastasis, pathological fracture, Enneking staging, and surgical margin were independent risk factors for prognosis. IV Therapic.
Identifiants
pubmed: 39363319
doi: 10.1186/s13018-024-05098-9
pii: 10.1186/s13018-024-05098-9
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
621Subventions
Organisme : National Key Research and Development Program of China
ID : 2023YFB4706300
Organisme : National Key Research and Development Program of China
ID : 2023YFB4706300
Organisme : National Key Research and Development Program of China
ID : 2023YFB4706300
Organisme : National Key Research and Development Program of China
ID : 2023YFB4706300
Organisme : National Key Research and Development Program of China
ID : 2023YFB4706300
Organisme : Beijing Municipal Natural Science Foundation
ID : L212042
Organisme : Beijing Municipal Natural Science Foundation
ID : L212042
Organisme : Beijing Municipal Natural Science Foundation
ID : L212042
Organisme : Beijing Municipal Natural Science Foundation
ID : L212042
Organisme : Beijing Municipal Natural Science Foundation
ID : L212042
Informations de copyright
© 2024. The Author(s).
Références
Inwards CY, Bloem JL, Hogendoorn PCW. WHO Classification of Tumours. 5th ed. International Arctic Research Center; Lyon, France: 2020. Dedifferentiated chondrosarcoma; pp. 388–390. Soft Tissue and Bone Tumours. The WHO Classification of Tumours Editorial Board.
Dahlin DC, Beabout JW. Dedifferentiation of low-grade chondrosarcomas. Cancer. 1971;28(2):461–6.
doi: 10.1002/1097-0142(197108)28:2<461::AID-CNCR2820280227>3.0.CO;2-U
pubmed: 5566365
Mitchell AD, Ayoub K, Mangham DC, Grimer RJ, Carter SR, Tillman RM. Experience in the treatment of dedifferentiated chondrosarcoma. J Bone Joint Surg Br. 2000;82:55–61.
doi: 10.1302/0301-620X.82B1.0820055
pubmed: 10697315
Capanna R, Bertoni F, Bettelli G, Picci P, Bacchini P, Present D, Giunti A, Campanacci M. Dedifferentiated chondrosarcoma. J Bone Joint Surg Am. 1988;70:60–9.
doi: 10.2106/00004623-198870010-00010
pubmed: 3335575
Grimer RJ, Gosheger G, Taminiau A, et al. Dedifferentiated chondrosarcoma: prognostic factors and outcome from a European group. Eur J Cancer. 2007;43:2060–5.
doi: 10.1016/j.ejca.2007.06.016
pubmed: 17720491
Strotman PK, Reif TJ, Kliethermes SA, et al. Dedifferentiated chondrosarcoma: a survival analysis of 159 cases from the SEER database (2001–2011). J Surg Oncol. 2017;116:252–7.
doi: 10.1002/jso.24650
pubmed: 28420036
Mercuri M, Picci P, Campanacci L, Rulli E. Dedifferentiated chondrosarcoma. Skel Radiol. 1995;24:409–16.
doi: 10.1007/BF00941235
Dickey ID, Rose PS, Fuchs B, et al. Dedifferentiated chondrosarcoma: the role of chemotherapy with updated outcomes. J Bone Joint Surg Am. 2004;86(11):2412–8.
doi: 10.2106/00004623-200411000-00008
pubmed: 15523011
Bruns J, Fiedler W, Werner M, Delling G. Dedifferentiated chondrosarcoma?a fatal disease. J Cancer Res Clin Oncol. 2005;131(6):333–9.
doi: 10.1007/s00432-004-0648-6
pubmed: 15785935
Staals EL, Bacchini P, Mercuri M, Bertoni F. Dedifferentiated chondrosarcomas arising in preexisting osteochondromas. J Bone Joint Surg Am. 2007;89(5):987–93.
doi: 10.2106/JBJS.F.00288
pubmed: 17473135
Tsuda Y, Tsoi K, Stevenson JD, et al. Development and external validation of nomograms to predict sarcoma-specific death and disease progression after surgical resection of localized high-grade conventional primary central chondrosarcoma and dedifferentiated chondrosarcoma. Bone Joint J. 2020;102–B(12):1752–9.
doi: 10.1302/0301-620X.102B12.BJJ-2020-0810.R1
pubmed: 33249892
Gong LH, Su YB, Zhang W, Liu WF, Dong RF, Sun XQ, Zhang M, Ding Y. Dedifferentiated Central Chondrosarcoma: a clinical, histopathological, and immunohistochemical analysis of 57 cases. Front Med (Lausanne). 2021;8:746909.
doi: 10.3389/fmed.2021.746909
pubmed: 34631758
Laitinen MK, Evans S, Stevenson J, et al. Clinical differences between central and peripheral chondrosarcomas. Bone Joint J. 2021;103–B(5):984–90.
doi: 10.1302/0301-620X.103B5.BJJ-2020-1082.R2
pubmed: 33934657
Tsuda Y, Gregory JJ, Fujiwara T, Abudu S. Secondary chondrosarcoma arising from osteochondroma: outcomes and prognostic factors. Bone Joint J. 2019;101–B(10):1313–20.
doi: 10.1302/0301-620X.101B9.BJJ-2019-0190.R1
pubmed: 31564158
Miao R, Choy E, Raskin KA, et al. Prognostic factors in dedifferentiated chondrosarcoma: a retrospective analysis of a large series treated at a single institution. Sarcoma. 2019;2019:9069272.
doi: 10.1155/2019/9069272
pubmed: 31915413
pmcid: 6930709
Laitinen MK, Parry MC, Le Nail LR, Wigley CH, Stevenson JD, Jeys LM. Locally recurrent chondrosarcoma of the pelvis and limbs can only be controlled by wide local excision. Bone Joint J. 2019;101–B(3):266–71.
doi: 10.1302/0301-620X.101B3.BJJ-2018-0881.R1
pubmed: 30813783
Cranmer LD, Chau B, Mantilla JG, et al. Is Chemotherapy Associated with Improved overall survival in patients with Dedifferentiated Chondrosarcoma? A SEER database analysis. Clin Orthop Relat Res. 2022;480(4):748–58.
doi: 10.1097/CORR.0000000000002011
pubmed: 34648466
Rosen G, Marcove RC, Huvos AG, Caparros BI, Lane JM, Nirenberg A, Cacavio A, Groshen S. Primary osteogenic sarcoma: eight-year experience with adjuvant chemotherapy. J Cancer Res Clin Oncol. 1983;106(Suppl):55–67.
doi: 10.1007/BF00625054
pubmed: 6604058
Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res. 1980;(153):106–20.
Enneking WF, Dunham W, Gebhardt MC, Malawar M, Pritchard DJ. A system for the functional evaluation of reconstructive procedures after surgical treatment of tumors of the musculoskeletal system. Clin Orthop Relat Res. 1993;(286):241–6.
Hompland I, Ferrari S, Bielack S, et al. Outcome in dedifferentiated chondrosarcoma for patients treated with multimodal therapy: results from the EUROpean Bone over 40 Sarcoma Study. Eur J Cancer. 2021;151:150–8.
doi: 10.1016/j.ejca.2021.04.017
pubmed: 33990016
Tsukamoto S, Mavrogenis AF, Nitta Y, et al. A systematic review of Adjuvant Chemotherapy in Localized Dedifferentiated Chondrosarcoma. Curr Oncol. 2024;31(1):566–78.
doi: 10.3390/curroncol31010040
pubmed: 38275833
pmcid: 10813944
Staals EL, Bacchini P, Bertoni F. Dedifferentiated central chondrosarcoma. Cancer. 2006;106:2682–91.
doi: 10.1002/cncr.21936
pubmed: 16691621
Kawaguchi S, Sun T, Lin PP, et al. Does ifosfamide therapy improve survival of patients with dedifferentiated chondrosarcoma? Clin Orthop Relat Res. 2014;472:983–9.
doi: 10.1007/s11999-013-3360-5
pubmed: 24197392
Tsuda Y, Evans S, Stevenson JD, et al. Is the Width of a Surgical Margin Associated with the outcome of Disease in patients with Peripheral Chondrosarcoma of the Pelvis? A Multicenter Study. Clin Orthop Relat Res. 2019;477(11):2432–40.
doi: 10.1097/CORR.0000000000000926
pubmed: 31453886
pmcid: 6903848
Kozawa E, Nishida Y, Kawai A, Hayakawa K, Setsu N, Kawashima H, Iwata S, Tsuchiya H, Tsukushi S, Takenaka S, Imanishi J, Baba I, Nagano A, Morii T, Shirai T, Shimizu K, Kawano H. Clinical features and treatment outcomes of dedifferentiated and grade 3 chondrosarcoma: a multi-institutional study. Cancer Sci. 2022;113(7):2397–408.
doi: 10.1111/cas.15382
pubmed: 35485870
pmcid: 9277248
Liu C, Xi Y, Li M, et al. Dedifferentiated chondrosarcoma: radiological features, prognostic factors and survival statistics in 23 patients. PLoS ONE. 2017;12:e0173665.
doi: 10.1371/journal.pone.0173665
pubmed: 28301537
pmcid: 5354284
Dry SM. Dedifferentiation in bone and soft tissue sarcomas: how do we define it? What is prognostically relevant? Hum Pathol Published Online Febr 2, 2024.
Sambri A, Tuzzato G, Donati DM, De Paolis M, Bianchi G. Pathological fracture does not affect prognosis in dedifferentiated chondrosarcoma of the limbs. J Orthop Sci. 2021;26:473–7.
doi: 10.1016/j.jos.2020.04.013
pubmed: 32564907
Lex JR, Evans S, Stevenson JD, et al. Dedifferentiated chondrosarcoma of the pelvis: clinical outcomes and current treatment. Clin Sarcoma Res. 2018;8(1):23.
doi: 10.1186/s13569-018-0110-1
pubmed: 30559960
pmcid: 6293503
van Maldegem A, Conley AP, Rutkowski P, et al. Outcome of first-line systemic treatment for unresectable conventional, dedifferentiated, mesenchymal, and clear cell chondrosarcoma. Oncologist. 2019;24(1):110–6.
doi: 10.1634/theoncologist.2017-0574
pubmed: 30082492
Yokota K, Sakamoto A, Matsumoto Y, et al. Clinical outcome for patients with dedifferentiated chondrosarcoma: a report of 9 cases at a single institute. J Orthop Surg Res. 2012;7(1):38.
doi: 10.1186/1749-799X-7-38
pubmed: 23227977
pmcid: 3536662
Albergo JI, Gaston CL, Jeys LM, et al. Management and prognostic significance of pathological fractures through chondrosarcoma of the femur. Int Orthop. 2015;39(5):943–6.
doi: 10.1007/s00264-015-2706-x
pubmed: 25711397
Bramer JAM, Abudu A, Grimer RJ, et al. Do pathological fractures influence survival and local recurrence rate in bony sarcomas? Eur J Cancer. 2007;43(13):1944–51.
doi: 10.1016/j.ejca.2007.07.004
pubmed: 17698347
Italiano A, Mir O, Cioffi A, et al. Advanced chondrosarcomas: role of chemotherapy and survival. Ann Oncol. 2013;24(11):2916–22.
doi: 10.1093/annonc/mdt374
pubmed: 24099780
pmcid: 3811906
Dhinsa BS, DeLisa M, Pollock R, et al. Dedifferentiated chondrosarcoma demonstrating osteosarcomatous differentiation. Oncol Res Treat. 2018;41:456–60.
doi: 10.1159/000487803
pubmed: 29902785
Bui N, Dietz H, Farag S, Hirbe AC, Wagner MJ, Van Tine BA, Ganjoo K, Jones RL, Keedy VL, Davis E. J. A retrospective multi-institutional cohort analysis of clinical characteristics and outcomes in dedifferentiated chondrosarcoma. Cancers. 2023;15:2617.
doi: 10.3390/cancers15092617
pubmed: 37174084
pmcid: 10177459
Amer KM, Munn M, Congiusta D, Abraham JA, Basu Mallick A. Survival and prognosis of Chondrosarcoma subtypes: SEER Database Analysis. J Orthop Res. 2020;38(2):311–9.
doi: 10.1002/jor.24463
pubmed: 31498474
Chow W, Frankel P, Ruel C, et al. Results of a prospective phase 2 study of pazopanib in patients with surgically unresectable or metastatic chondrosarcoma. Cancer. 2020;126(1):105–11.
doi: 10.1002/cncr.32515
pubmed: 31509242